Benchtalk 2025: Kate Haviland discusses the $9B+ acquisition of Blueprint by Sanofi, being chair of Fulcrum, her thoughts on M&A, and what is interesting in biotech today

The CEO of Blueprint (up to the acquisition) discusses the company's success factors, and being led to immunology by the science. Plus, why she believes an oral pill that is disease modifying, like Fulcrum is trying to develop, is strongly needed for the sickle cell patient community.